Evidence map›Paper›PMID 42419270›Full record

ReviewCell host & microbe2026

Engineering commensal microbes for host health.

Elizabeth A Brown, Arianna Brevi, David M Zong, Amir Zarrinpar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell host & microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elizabeth A BrownDivision of Gastroenterology, University of California, San Diego, La Jolla, CA, USA.
Arianna BreviDivision of Gastroenterology, University of California, San Diego, La Jolla, CA, USA.
David M ZongDivision of Gastroenterology, University of California, San Diego, La Jolla, CA, USA.
Amir ZarrinparDivision of Gastroenterology, University of California, San Diego, La Jolla, CA, USA; Division of Gastroenterology, Jennifer Moreno Department of Veterans Affairs Medical Center, La Jolla, CA, USA; Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA; Shu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; School of Biological Sciences, University of California, San Diego, La Jolla, CA, USA; Synthetic Biology Institute, University of California, San Diego, La Jolla, CA, USA. Electronic address: azarrinpar@health.ucsd.edu.

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MILES Frome WILKINSON · 2003 to 2026
$40.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Regulation of Glycogen in Health and DiseaseR01DK117551 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALAN R. SALTIEL · 2018 to 2026
$3.8M
Engineering Native E. coli to Detect, Report, and Treat Colorectal CancerU01CA265719 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZARRINPAR, AMIR · 2021 to 2025
$3.1M
Development of Engineered Native Bacteria as a Tool for Functional Manipulation of the Gut MicrobiomeR01AI163483 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEFF M HASTY, Amir Zarrinpar · 2023 to 2026
$3.1M
Design and characterization of bacterial population dynamics in solid tumor modelsR01EB030134 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HASTY, JEFF M, TSIMRING, LEV S · 2021 to 2024
$2.5M
Colorectal Cancer Therapies Introduced Through Engineered Native BacteriaR01CA310170 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Amir Zarrinpar · 2026 to 2026
$671k
The Impact of Bile Salt Hydrolase on Intestinal T Cells in ColitisF31DK145221 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Elizabeth A Brown · 2026 to 2026
$44k
NCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA014195NCI NIH HHS R01 CA310170NCI NIH HHS U01 CA265719NIAID NIH HHS R01 AI163483NIBIB NIH HHS R01 EB030134NIDDK NIH HHS F31 DK145221NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK117551ORD VA I01 RD001332
6 · The paper itself

Abstract

Engineered live biotherapeutic products (eLBPs) represent an emerging class of programmable microbial therapies capable of sensing and responding to host physiology. Advances in microbiome science and synthetic biology have driven the development of engineered bacteria that deliver therapeutic molecules, modulate host metabolism, or detect disease-associated signals. In this review, we summarize recent progress in the development of eLBPs across diverse disease indications, including inflammatory diseases, metabolic disorders, cancer, and infectious diseases. We highlight key factors that drive successful eLBP design, including chassis selection, methods for DNA delivery, approaches for tuning therapeutic expression, and genetic systems for biocontainment. Although early clinical studies demonstrate promising safety profiles, challenges remain in achieving predictable colonization, durable therapeutic activity, and robust biocontainment in vivo. By synthesizing advances across these areas, we propose a framework for the rational design of next-generation eLBPs that can more reliably translate from experimental systems to clinical application.

Indexed as

Biological TherapyGenetic EngineeringMicrobiotaMicroorganisms, Genetically-ModifiedAnimalsBacteriaHumansMetabolic DiseasesNeoplasmsSynthetic BiologyauxotrophycalprotectinCRISPR-associated transposasescurli fibersEngraftmentEscherichia coli Nissle 1917horizontal gene transferkill switchesmemory circuitsmucosal deliveryporphyrinQuorum sensing

Identifiers

PMID42419270
PMCPMC13585459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.